Overview

Pharmacoinvasive Therapy With Prourokinase

Status:
Completed

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to elucidate the efficacy and safety of pharmacoinvasive therapy by using prourokinase (prouk), a unique fibrin-specific agent, in patients with ST-segment elevation myocardial infarction (STEMI)

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Suzhou Landing Pharmaceuticals

Treatments:

Saruplase